PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PTC THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$61.53+2.29 (+3.87%)
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
PTC THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration and license revenue | $998.36M | $304.00K | $100.03M | – | – | – | – | – | – | – | 57.7% | +328306.9% |
| Net product revenue | $586.70M | $582.15M | $638.18M | $535.23M | $428.90M | $333.40M | $291.31M | $263.01M | $174.07M | $81.45M | 33.9% | +0.8% |
| Royalty revenue | $244.22M | $203.86M | $168.86M | $113.52M | $54.64M | $4.79M | – | – | – | – | 14.1% | +19.8% |
| Translarna | $235.30M | $321.07M | $332.75M | – | – | – | – | – | – | – | 13.6% | -26.7% |
| Emflaza | $146.36M | $207.22M | $255.09M | – | – | – | – | $92.00M | $28.80M | – | 8.5% | -29.4% |
| Sephience | $111.15M | – | – | – | – | – | – | – | – | – | 6.4% | – |
| Upstaza/Kebilidi | $56.63M | $16.91M | $18.84M | – | – | – | – | – | – | – | 3.3% | +234.8% |
| All other products | $37.26M | $36.95M | $31.50M | – | – | – | – | – | – | – | 2.2% | +0.9% |
| Manufacturing revenue | $0 | $1.66M | $7.69M | $0 | $0 | – | – | – | – | – | 0.0% | -100.0% |
| Translarna | -$98.63M | $18.81M | $23.07M | – | – | – | – | $171.00M | $145.20M | $81.40M | -5.7% | -624.5% |
| Licensing And Collaboration Agreement | – | – | – | – | – | – | $15.20M | $200.00K | $20.30M | $400.00K | – | – |
| Collaboration revenue | – | – | – | $50.05M | $55.05M | $42.58M | $15.67M | $1.73M | $20.33M | $1.26M | – | – |
| Grant [Member] | – | – | – | – | – | – | – | $0 | – | $900.00K | – | – |
| Collaboration revenue | – | $304.00K | $100.03M | $50.05M | $55.05M | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $252.19M | $207.22M | $255.09M | $381.86M | $297.01M | $186.40M | $116.68M | $93.69M | $49.16M | $1.21M | 14.6% | +21.7% |
| International | $235.89M | $393.74M | $406.16M | $316.94M | $241.59M | $194.37M | $190.30M | $171.04M | $145.24M | $81.50M | 13.6% | -40.1% |
| All other countries | $168.41M | $197.47M | $238.51M | – | – | – | – | – | – | – | 9.7% | -14.7% |
| Russia | $100.45M | $105.38M | $85.97M | – | – | – | – | – | – | – | 5.8% | -4.7% |
| Brazil | $65.66M | $72.08M | $58.61M | – | – | – | – | – | – | – | 3.8% | -8.9% |
From the segment and revenue-disaggregation notes of Ptc Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.